Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Guangzhou Innogen Pharmaceutical Group Co Ltd Class H ( (HK:2591) ) is now available.
Guangzhou Innogen Pharmaceutical Group Co., Ltd. announced that its core product, Efsubaglutide Alfa, has been included in China’s National Reimbursement Drug List (NRDL) for type 2 diabetes treatment, effective January 2026. This inclusion is expected to enhance the company’s market positioning by increasing accessibility and adoption of Efsubaglutide Alfa, which has shown significant efficacy and safety in clinical trials.
More about Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
Guangzhou Innogen Pharmaceutical Group Co., Ltd. is a pharmaceutical company based in China, focusing on the development of innovative drugs. Its primary product, Efsubaglutide Alfa, is a humanised and long-acting GLP-1 receptor agonist designed for the treatment of type 2 diabetes and other metabolic diseases.
Average Trading Volume: 501,191
Learn more about 2591 stock on TipRanks’ Stock Analysis page.